Ziccum AB is pioneering a novel drying technology known as LaminarPace, which utilizes a unique Mass Transfer drying method to enhance the stability and usability of biologics and mRNA therapeutics. This innovative approach allows for the transformation of sensitive liquid formulations into robust, storage-friendly powders without the application of extreme heat, thereby preserving the integrity of delicate biological materials. LaminarPace is particularly advantageous for the development of next-generation vaccines and therapeutics, as it enables high process yields of around 80%, significantly reducing waste compared to traditional drying methods. The technology is designed to be seamlessly integrated into biopharmaceutical manufacturing processes, facilitating a more efficient and cost-effective production environment.

In addition to its drying capabilities, Ziccum focuses on three strategic vaccine platforms: mRNA/LNP, viral vector, and protein subunit vaccines. The company is actively engaged in research and development to optimize the thermostability of these platforms, which are critical for the advancement of personalized and cancer vaccines. Ziccum's commitment to innovation is further demonstrated through collaborations with research institutions and the application of advanced 3D modeling techniques to enhance the scalability and efficiency of LaminarPace. By addressing the challenges of stability and delivery in biopharmaceuticals, Ziccum aims to expand the possibilities for drug administration routes and improve the overall efficacy of vaccine formulations.

Sweden

Ziccum is developing new dry-powder versions of the world’s most urgently-needed vaccines. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

Ziccum AB

Company Details